NEW YORK – In acquiring longtime partner Boston Genomics this week, Genomenon is stepping up its efforts to become the first entity to curate the entire human genome, though it may be the only one to have declared such an intention.

By adding Cambridge, Massachusetts-based Boston Genetics’ team of about 75 genetic scientists — and doubling its total headcount — Genomenon now claims to have an inside track toward its goal, which CEO Mike Klein said is intended to combine artificial intelligence and next-generation sequencing to accelerate diagnosis of rare diseases and inform drug discovery.

“We’ll organize all the disease-gene relationships, we’ll organize all the variant landscapes across every disease, to really provide the insight for precision medicine,” Klein said.

While nobody else has publicly declared a similar intention, Klein has been talking about a “race” to curate the complete human genome, and the firm has been on this mission for several years on the back of its flagship product, the AI-powered Mastermind Genomic Search Engine.

Genomenon’s focus has evolved from building an AI-enabled genomic search engine to curating

Funding supports Phase 2 clinical study of ONL1204 Ophthalmic Solution to evaluate safety and efficacy in patients with macula-off rhegmatogenous retinal detachment

ANN ARBOR, Mich., March 8, 2023 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round. Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).

“With the support of our current and new investors, coupled with the opening of our IND for ONL1204 last month, we are grateful for the opportunity to advance our lead asset into a later stage Phase 2 clinical study,” said David Esposito, chief executive officer of ONL Therapeutics. “We expect to initiate this new U.S.-based Phase 2 study in acute retinal detachment next quarter and to continue to generate data throughout the year from our two ongoing chronic

A Zeeland furniture startup that seeks to play into the growing home office trend has secured $1.5 million in capital from investors around Michigan.

Quint Workspaces LLC, formed in 2020 by office furniture industry veteran Don Goeman, plans to use the early-stage funding to support new product development, expand delivery services to major markets, and enhance e-commerce capabilities.

“This round of funding moves Quint fully into launch and accessibility mode allowing us to quickly deliver affordable, high quality products to our new and existing customers,” said Goeman, the founder and CEO of Quint Workspaces who intends to open a new office and production facility in West Michigan later this year.

“The value of our products and manufacturing approach is already being validated by our customers, and our business model is proving to be scalable and ready to expand throughout the country,” he said.

Goeman previously worked for 40 years at the former Herman Miller Inc., now MillerKnoll Inc. He served as executive vice president of research, design and development from 2005 to 2019 before forming Quint Workspaces